Clinical trials: open to volunteers, sponsored by AstraZeneca
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Uncontrolled Hypertension
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average…
- Trial name
- BaxNoD (NCT07686120)
- Testing
- baxdrostat 2mg
- Where
- 51 sites in China
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received…
- Trial name
- EvoPAR-PR05 (NCT07711002)
- Testing
- Saruparib, Enzalutamide, Darolutamide
- Where
- 210 sites in United States, Austria and 19 more
- Volunteers
- 1,330 people
- Sponsor
- AstraZeneca
Muscle-Invasive Bladder Cancer (MIBC)
A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive
This is a Phase 4, Single Arm Study To Assess The Safety and tolerability of Perioperative Durvalumab in Combination with Neoadjuvant Gemcitabine Plus Cisplatin Treatment Followed by radical cystectomy and Durvalumab alone as…
- Trial name
- SERENE (NCT07876817)
- Testing
- Durvalumab, Gemcitabine, Cisplatin
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL)
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who…
- Conditions
- B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
- Trial name
- SOUNDTRACK-B (NCT06526793)
- Testing
- Surovatamig
- Where
- 94 sites in United States, Australia and 14 more
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours…
- Trial name
- RHEA-1 (NCT06795022)
- Testing
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
B-cell Non-Hodgkin Lymphoma
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin…
- Trial name
- Lumi-NHL (NCT07123454)
- Testing
- AZD4512
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 91 people
- Sponsor
- AstraZeneca
Rare Diseases, Generalized Myasthenia Gravis (gMG)
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR)…
- Trial name
- NCT07247279
- Where
- 7 sites in Russia
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Lupus Erythematosus, Systemic
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
VIOLET is a prospective, single-arm, multi-centre, non-interventional study (NIS) evaluating real-world clinical and patient-reported outcome (PRO) data in adult patients who are initiated on subcutaneous anifrolumab treatment of…
- Trial name
- VIOLET (NCT07424261)
- Where
- 21 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Metastatic Prostate Cancer
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
- Trial name
- PROSPECTOR (NCT07590934)
- Testing
- AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
HepatoCellular Carcinoma
CHARM Hepatocellular Carcinoma MEA Study
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death worldwide.
- Trial name
- NCT07650773
- Where
- 17 sites in Egypt, Kuwait and 5 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Breast Cancer, Biliary Tract Carcinoma
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
- Conditions
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT05123482
- Testing
- AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib)
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca
Life Threatening Bleeding, Factor Xa Inhibitor
Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)
This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg.
- Trial name
- NCT05454787
- Where
- 54 sites in Japan
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca
Asthma
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or…
- Trial name
- HORIZON (NCT06023589)
- Testing
- Tezepelumab
- Where
- 147 sites in United States, Argentina and 20 more
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in…
- Trial name
- SYRUS (NCT06137118)
- Testing
- Surovatamig
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin Lymphoma
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in…
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
- Trial name
- PRIMAVERA (NCT06137144)
- Testing
- AZD3470, Pembrolizumab
- Where
- 38 sites in United States, Australia and 9 more
- Volunteers
- 161 people
- Sponsor
- AstraZeneca
Heart Failure and Impaired Kidney Function
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event.
- Trial name
- BalanceD-HF (NCT06307652)
- Where
- 852 sites in United States, Argentina and 37 more
- Volunteers
- 3,850 people
- Sponsor
- AstraZeneca
Asthma
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma…
- Trial name
- ACADIA (NCT06307665)
- Testing
- BDA MDI, AS MDI
- Where
- 155 sites in United States, China and 2 more
- Volunteers
- 440 people
- Sponsor
- AstraZeneca